U.S. markets open in 4 hours 27 minutes

Silverback Therapeutics, Inc. (SBTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
38.29+4.21 (+12.35%)
At close: 4:00PM EDT

Silverback Therapeutics, Inc.

500 Fairview Avenue North
Suite 600
Seattle, WA 98109
United States
206 456 2900
http://www.silverbacktx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees54

Key Executives

NameTitlePayExercisedYear Born
Dr. Peter A. Thompson M.D.Co-Founder & Chairman of DirectorsN/AN/A1959
Dr. Valerie Odegard Ph.D.Pres & Chief Scientific Officer415.09kN/A1977
Dr. Naomi Hunder M.D.Chief Medical Officer426.54kN/A1969
Dr. Laura K. ShawverCEO & DirectorN/AN/A1958
Mr. Jonathan PiazzaChief Financial OfficerN/AN/A1975
Mr. Jeffrey C. Pepe J.D., Ph.D.Sr. VP & Gen. CounselN/AN/AN/A
Katie CarriganVP of HRN/AN/AN/A
Mr. Russ HawkinsonSr. VP of Fin.N/AN/AN/A
Mr. Scott Moorefield Ph.D.Sr. VP of Bus. Devel.N/AN/AN/A
Mr. Sateesh NatarajanSr. VP of CMC Devel.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Corporate Governance

Silverback Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.